Asset Management One Co. Ltd. Has $4.84 Million Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN

Asset Management One Co. Ltd. raised its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 8.8% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 87,963 shares of the biotechnology company’s stock after buying an additional 7,084 shares during the quarter. Asset Management One Co. Ltd.’s holdings in BioMarin Pharmaceutical were worth $4,835,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. V Square Quantitative Management LLC acquired a new stake in shares of BioMarin Pharmaceutical during the 2nd quarter worth $25,000. Rise Advisors LLC acquired a new stake in shares of BioMarin Pharmaceutical during the 1st quarter worth $30,000. Brooklyn Investment Group grew its holdings in shares of BioMarin Pharmaceutical by 2,250.0% during the 1st quarter. Brooklyn Investment Group now owns 564 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 540 shares in the last quarter. Banque Transatlantique SA acquired a new stake in shares of BioMarin Pharmaceutical during the 1st quarter worth $71,000. Finally, IFP Advisors Inc grew its holdings in shares of BioMarin Pharmaceutical by 1,382.2% during the 2nd quarter. IFP Advisors Inc now owns 1,749 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 1,631 shares in the last quarter. 98.71% of the stock is owned by institutional investors and hedge funds.

BioMarin Pharmaceutical Price Performance

BioMarin Pharmaceutical stock opened at $53.49 on Wednesday. The company has a current ratio of 5.56, a quick ratio of 3.60 and a debt-to-equity ratio of 0.10. The company has a market capitalization of $10.27 billion, a PE ratio of 20.11, a P/E/G ratio of 0.66 and a beta of 0.33. BioMarin Pharmaceutical Inc. has a 12 month low of $51.56 and a 12 month high of $73.51. The stock has a 50-day moving average price of $55.12 and a two-hundred day moving average price of $57.20.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. UBS Group increased their target price on BioMarin Pharmaceutical from $113.00 to $114.00 and gave the stock a “buy” rating in a report on Tuesday, August 5th. JPMorgan Chase & Co. increased their target price on BioMarin Pharmaceutical from $116.00 to $119.00 and gave the stock an “overweight” rating in a report on Thursday, October 9th. Raymond James Financial initiated coverage on BioMarin Pharmaceutical in a report on Wednesday, September 3rd. They set an “outperform” rating and a $85.00 target price on the stock. Guggenheim raised their price objective on BioMarin Pharmaceutical from $101.00 to $106.00 and gave the company a “buy” rating in a research note on Wednesday, August 6th. Finally, Truist Financial reduced their price objective on BioMarin Pharmaceutical from $90.00 to $80.00 and set a “buy” rating on the stock in a research note on Tuesday. Seventeen analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, BioMarin Pharmaceutical has a consensus rating of “Moderate Buy” and a consensus target price of $89.91.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.